|
CN110785167A
|
|
Methods and compositions relating to bucindolol for the treatment of atrial fibrillation
|
|
CA2822747A1
|
|
Use of s-(6-nitro-oxi-hexahydro-furo[3,2-b]thioacetate in the treatment of cardiovascular disorders associated with oxide synthase dysfunction
|
|
WO2011032088A1
|
|
Polymorphisms in the pde3a gene
|
|
US2010305003A1
|
|
Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
|
|
US2010292155A1
|
|
Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
|
|
CA2732513A1
|
|
Methods and compositions involving (s)-bucindolol
|
|
AU2007234602A1
|
|
Methods of therapy and diagnosis
|
|
AU2007296498A1
|
|
Methods for treating cancer
|
|
AU2003213064A1
|
|
Methods of therapy and diagnosis
|
|
EP2228443A1
|
|
Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
|
